← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.08T	4,643	+253	+6%	$943B
2	2 Amgen AMGN $230B	3,164	+12	+0.4%	$162B
3	3 Pfizer PFE $166B	2,841	-122	-4%	$91.9B
4	4 McKesson MCK $114B	2,020	-29	-1%	$79.8B
5	5 AstraZeneca AZN $251B	1,507	+122	+9%	$196B
6	6 Becton Dickinson BDX $51.5B	1,445	-30	-2%	$41.2B
7	7 Novo Nordisk NVO $168B	1,356	+77	+6%	$15.7B
8	8 Regeneron Pharmaceuticals REGN $80.1B	1,340	-60	-4%	$57.1B
9	9 ResMed RMD $33.1B	891	-54	-6%	$19.4B
10	10 West Pharmaceutical WST $26.4B	834	+79	+10%	$25.2B
11	11 Conagra Brands CAG $6.61B	788	-4	-0.5%	$5.71B
12	12 Teva Pharmaceutical Industries Limited TEVA $47.5B	676	+23	+4%	$24.7B
13	13 DaVita DVA $11.5B	631	+47	+8%	$13.1B
14	14 Lamb Weston LW $7.31B	559	-8	-1%	$5.63B
15	15 Hims & Hers Health HIMS $6.47B	506	+70	+16%	$5.39B
16	16 The Magnum Ice Cream Company N.V. MICC $11B	485	-13	-3%	$4.65B
17	17 Viking Therapeutics VKTX $3.24B	436	+22	+5%	$2.95B
18	18 Madrigal Pharmaceuticals MDGL $10.6B	414	+34	+9%	$12.7B
19	19 BellRing Brands BRBR $1.01B	365	-13	-3%	$1.7B
20	20 Embecta EMBC $350M	322	-18	-5%	$165M
21	21 Scholar Rock SRRK $4.82B	306	+32	+12%	$7.63B
22	22 Rhythm Pharmaceuticals RYTM $5.97B	305	+20	+7%	$8.55B
23	23 Biohaven BHVN $1.65B	296	+18	+6%	$2.1B
24	24 Inspire Medical Systems INSP $1.97B	275	-26	-9%	$1.65B
25	25 MannKind Corp MNKD $971M	260	+10	+4%	$776M